December 2012 Volume 3 - Issue 4

Page 1

Volume 3 — Issue 4

The SSC’s Official Science Newspaper

thecurrent@westernssc.ca

Good morning, Dr. Kang The Current Editor Ivan Urosev

sits down with Dr. Chil-Yong Kang to discuss his past research and possible ideas for the future.

.

The excitement regarding the recent news in the development of the SAV001 HIV vaccine here at Western has spilled over beyond the faculty of science, and has propelled the project's lead researcher, Dr. Chil-Yong Kang, into the world of academic celebrity. Despite the attention, Dr. Kang remains cautiously humble about what the future holds, perhaps a testament to the journey that has brought him to this point. Born in Korea in the 1940's, Dr. Kang's academic career began with a boat journey to the West which took 40 days and 40 nights, and has culminated with his virology research here at Western.

THE CURRENT: Dr. Kang, thank you for

taking the time to talk to us. You’ve mentioned that you have been working on HIV research for 20 years now. Can you elaborate on that 20 year process?

Dr. Kang:

HIV research was easy for us to start because we’ve been working on retroviruses before. The

retrovirus is the group of viruses which HIV belongs to. So, I’ve been working on retroviruses since, you know, mid-seventies when I was a post-doctoral fellow. And then worked on, its called avian retroviruses, avian sarcoma virus, avian leukosis virus and also avian reticulendotheliosis virus. Those are all retroviruses. So, in the

INSIDE THIS ISSUE, YOU’RE GOING TO FIND... 4D’s haven’t been this interesting since the time those two female lifeguards saved you from drowning. Page 3 Scientific reasoning behind the supposed looming apocalypse. Page 4-5 Famous birthdays: James Prescott Joule.

Page 6

What’s more powerful than a geomagnetic storm? Two geomagnetic storms. Page 7 The best damn comics section in the league.

Page 8

Follow us on twitter! We know how to give you a raging hadron...

early 80s HIV was discovered, and that was one of the retroviruses that I thought the problem would be solved very soon. But the late 80’s, we started with HIV work about 87, 88.

Dr. Kang:

No, I was at the University of Ottawa. I was the chair of microbiology and immunology department at the University of Ottawa medical school. And so we decided “oh well lets do some basic research on HIV”. So, the transition from other retroviruses into HIV was relatively easy for us. So we did a lot of those fundamental studies of HIV at that time...Then, unexpectedly, people could not figure out how to make a vaccine against HIV. People tried so many different strategies, but they did not work. Any

particular

Dr. Kang:

reasons

signal peptide. Which produces large amounts of the glycoprotein, and processes them really adequately. That enhances virus production; faster and more.

TC:

TC: Was that here at Western?

TC:

@TheCurrent_SSC

for

that?

Well, that difficulty still stands. First of all, there’s no animal model for HIV vaccine efficacy test. So even if you have an experimental vaccine developed you cannot test it, in any animals other than humans. So you have to test it in humans. That’s one really, reason why HIV, the progress of HIV vaccine research is so slow. Second one, is no one seemed to know what strategy one should use to make a vaccine effective in preventing HIV infection. People have tried subunit vaccines, people have tried recombinant virus vaccines, but these strategies did not work... So we’re left with one strategy which was not tried, and this is the killed whole-virus strategy. Why? There were two problems with that. Number one, its too dangerous to produce large quantities. Secondly there was no system to produce enough quantity to make vaccines. And we solved those two problems by genetically modifying the genes of HIV. We took out the NEF gene, which we know is responsible for pathogenesis, so we took it out. And secondly we modified the signal peptide which governs the biosynthesis of the glycoprotein, surface antigen. And so we replaced this natural signal peptide, with a totally exogenous signal peptide which comes from the honeybee. Honeybee mellitin, which is a honeybee toxin

Moving off the actual vaccine, you’re waiting to be interviewed by Chinese television following this. How do you feel about the media response in regards to the vaccine, and your celebrity personally, at least on campus?

Dr. Kang:

I’m trying to downplay this, because we don’t know whether this vaccine will prevent HIV infection. We are doing our best, to see whether this strategy will work, because this strategy worked for other viral diseases... Now how do I feel? I don’t want to be overly enthusiastic about this because I’m a very cautious person. There were so many failures in the past, I don’t want to blow my horn yet, until we see that there is a definite strong efficacy of our vaccine. I’m cautiously optimistic.

[In the future] what I would like to do is provide an adequate amount of funding, guaranteed for 10 years, for each faculty member. - Dr. Kang

TC:

for

Can you tell me about your plans a world institute of virology?

Dr. Kang:

Well an idea, and also I introduced this idea, its my dream. [I need] someone who is influential and who is governing a country, and also who has a really philanthropic mind, and those who have the funds to support this kind of institute. And also I’ve been talking to the business people who might be interested in sponsoring this. Because this can really establish a very; on solid ground this kind of institution will establish a company, or country or individual, as high impact as Nobel. [Nobel] created his.. wealth with the discovery of dynamite and donated that money to recognize people who

...CONTINUED ON PAGE 6

The sole responsibility for the content of this publication lies with the authors. Its contents do not reflect the opinion of the University Students’ Council of the University of Western Ontario (“USC”). The USC assumes no responsibility or liability for any error, inaccuracy, omission or comment contained in this publication or for any use that may be made of such information by the reader.


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.